CRGX
CARGO Therapeutics, Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website cargo-tx.com
- Employees(FY) 42
- ISIN US14179K1016
Performance
+14.67%
1W
+19.96%
1M
+61.56%
3M
+10.47%
6M
-3.41%
YTD
+53.89%
1Y
Profile
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.
Technical Analysis of CRGX 2024-11-08
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-11-05 16:05
- 2024-11-05 09:23
- 2024-11-05 03:05
- 2024-11-04 20:23
- 2024-10-18 10:06
- 2024-08-16 18:50
- 2024-08-16 08:53
- 2024-08-12 16:05
- 2024-08-12 04:05
- 2024-07-29 09:52
- 2024-07-22 08:14
- 2024-07-10 08:00
- 2024-07-09 20:00
- 2024-06-04 16:05
- 2024-06-04 04:05
- 2024-06-04 01:56
- 2024-05-30 06:00
- 2024-05-29 18:00
- 2024-05-28 08:05
- 2024-05-28 08:00
- 2024-05-27 20:05
- 2024-05-27 20:00
- 2024-05-22 12:00
- 2024-05-22 09:55
- 2024-05-22 00:00
- 2024-05-21 21:55
- 2024-05-14 16:05
- 2024-05-14 09:54
- 2024-05-14 04:05
- 2024-05-09 07:36
Page 1 of 2
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment.